 |
|
|
|
 |
|
|
| Article 1 to 10 out of 10 concerning Bio*One Capital Pte Lt
|
-
Singapore's first commercial developer of molecular diagnostic assays commences operation
(11 Sep 2008)
Dx Assays Pte Ltd, announced that it has officially started its operations. The company was established end 2007, as a joint venture between QIAGEN and Bio*One Capital. Dx Assays was formally launched at an opening ceremony attended by some 50 ...
-
Singapore's first commercial developer of molecular diagnostic assays opens operations
(03 Sep 2008)
Dx Assays Pte Ltd will commence operations on 8 September, as Singapore’s first commercial developer of molecular diagnostic assays, according to the compay. The company will develop and validate molecular diagnostic assays for biotech and ...
-
QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products
(05 Dec 2007)
Assay development centre for Singapore will support QIAGEN in the market for molecular testing solutions
QIAGEN and Bio*One Capital announced that they have entered into a joint venture to establish Dx Assays Pte Ltd ("Dx Assays"). Dx Assays expects to be one of the first centres in Singapore for assay development in which molecular diagnostics for ...
-
Codexis Opens Singapore Laboratory
(26 Oct 2007)
Codexis, Inc. announced the opening of Codexis Laboratories Singapore Pte. Ltd. (CLS). CLS is the company's first research facility in Asia, and is an expansion of the company's research and development operations in the U.S. and Europe. CLS will ...
-
Lonza and Bio*One Capital to Invest in Second Large Scale Commercial Mammalian Cell Culture Manufacturing Facility
(08 Dec 2006)
Lonza Group Ltd and Singapore's Bio*One Capital announce the signing of a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell culture facility in Singapore for the manufacture of commercial biopharmaceuticals. This will be the ...
-
Codexis to Establish New R&D Facility in Singapore to Support Expanding Generics Business
(28 Aug 2006)
Codexis announced that it will establish a research and development center in Singapore, scheduled to open in the third quarter of 2007. The R&D center will focus on new product development for the company's API and generics business. When fully ...
-
MerLion Pharmaceuticals announces the completion of a merger with Combinature Biopharm AG and Athelas SA
(23 Aug 2006)
MerLion Pharmaceuticals Pte Ltd (MerLion) of Singapore has completed a merger by exchange of shares with Combinature Biopharm AG and Athelas SA. Both European companies become 100% subsidiaries of MerLion whose headquarters and drug discovery ...
-
New Biomedical Sciences Executive Committee Established to Lead Phase 2 of Singapore's Biomedical Sciences Initiative
(01 Aug 2006)
Singapore's Biomedical Sciences (BMS) initiative was launched in the middle of year 2000. The first five years have seen much success. Working with other agencies, A*STAR has established the core infrastructure and scientific capabilities for basic ...
-
Combinatorx and Bio*One Capital Establish Combinatorx Singapore for Infectious Disease Product Discovery and Development
(23 Jan 2006)
Sir David Lane to join the Board of Directors of CombinatoRx Singapore
CombinatoRx, Incorporated and Bio*One Capital of Singapore announced the establishment of CombinatoRx Singapore Pte Ltd. CombinatoRx Singapore and Bio*One also announced that Sir David Lane has joined the CombinatoRx Singapore Board of Directors. ...
-
Bio*One Capital's A-Bio Pharma Secures A Second Deal With GlaxoSmithKline
(18 Aug 2005)
$9 million Expansion of Facility Underway
Bio*One Capital Pte Ltd, a leading biomedical sciences investment management company, announced that its portfolio company A-Bio Pharma Pte Ltd (A-Bio), has clinched its second process development and clinical supply service agreement with ...
|
|
|
|
|
Top